After the grape rush: Sirtuins as epigenetic drug targets in neurodegenerative disorders

2011 ◽  
Vol 19 (12) ◽  
pp. 3616-3624 ◽  
Author(s):  
Kilian Huber ◽  
Giulio Superti-Furga
2016 ◽  
Vol 22 (999) ◽  
pp. 1-1
Author(s):  
Karmen Stankov ◽  
Sunčica Stankov ◽  
Jasmina Katanić

2016 ◽  
Vol 12 ◽  
pp. P1192-P1192 ◽  
Author(s):  
Tamara Maes ◽  
Cristina Mascaró ◽  
David Rotllant ◽  
Fernando Cavalcanti ◽  
Elena Carceller ◽  
...  

2004 ◽  
Vol 165 (1) ◽  
pp. 27-30 ◽  
Author(s):  
Laura Korhonen ◽  
Dan Lindholm

The ubiquitin proteasome system (UPS) contributes to the pathophysiology of neurodegenerative diseases, and it is also a major determinant of synaptic protein degradation and activity. Recent studies in rodents and in the fruit fly Drosophila have shown that the activity of the UPS is involved in axonal degeneration. Increased knowledge of the UPS in synaptic and axonal reactions may provide novel drug targets for treatments of neuronal injuries and neurodegenerative disorders.


2012 ◽  
Vol 16 (07) ◽  
pp. 54-57

German biotech innovator Altona Diagnostics launches BioNexus-certified regional hub in Malaysia: ADT Biotech Sdn Bhd. FEI launches "Explore the Unseen" image contest in partnership with National Geographic. BIO applauds Representative Kaptur's Energy Investment Act of 2012. Cytori to utilize Sistemic's SistemQC™ to strengthen understanding of mechanisms & support design of Next-Generation Cell Therapies. Bosch packaging technology and Sartorius Stedim Biotech introduce PreVAS. CellCentric and ZoBio enter into partnership to develop lead compounds against epigenetic drug targets.


Epigenomics ◽  
2019 ◽  
Vol 11 (13) ◽  
pp. 1463-1467
Author(s):  
Karol Bomsztyk ◽  
Yuliang Wang
Keyword(s):  

2020 ◽  
Vol 21 (11) ◽  
pp. 4134 ◽  
Author(s):  
Balázs Zoltán Zsidó ◽  
Csaba Hetényi

Development of valid structure–activity relationships (SARs) is a key to the elucidation of pathomechanisms of epigenetic diseases and the development of efficient, new drugs. The present review is based on selected methodologies and applications supplying molecular structure, binding affinity and biological activity data for the development of new SARs. An emphasis is placed on emerging trends and permanent challenges of new discoveries of SARs in the context of proteins as epigenetic drug targets. The review gives a brief overview and classification of the molecular background of epigenetic changes, and surveys both experimental and theoretical approaches in the field. Besides the results of sophisticated, cutting edge techniques such as cryo-electron microscopy, protein crystallography, and isothermal titration calorimetry, examples of frequently used assays and fast screening techniques are also selected. The review features how different experimental methods and theoretical approaches complement each other and result in valid SARs of the epigenome.


RSC Advances ◽  
2019 ◽  
Vol 9 (34) ◽  
pp. 19571-19583 ◽  
Author(s):  
Feifei Yang ◽  
Na Zhao ◽  
Di Ge ◽  
Yihua Chen

Histone deacetylases (HDACs) are clinically validated epigenetic drug targets for cancer treatment.


2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Saba Sheikh ◽  
Safia ◽  
Ejazul Haque ◽  
Snober S. Mir

Neurodegenerative diseases are multifactorial debilitating disorders of the nervous system that affect approximately 30 millionindividuals worldwide. Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and amyotrophic lateral sclerosis diseases are the consequence of misfolding and dysfunctional trafficking of proteins. Beside that, mitochondrial dysfunction, oxidative stress, and/or environmental factors strongly associated with age have also been implicated in causing neurodegeneration. After years of intensive research, considerable evidence has accumulated that demonstrates an important role of these factors in the etiology of common neurodegenerative diseases. Despite the extensive efforts that have attempted to define the molecular mechanisms underlying neurodegeneration, many aspects of these pathologies remain elusive. However, in order to explore the therapeutic interventions directed towards treatment of neurodegenerative diseases, neuroscientists are now fully exploiting the data obtained from studies of these basic mechanisms that have gone awry. The novelty of these mechanisms represents a challenge to the identification of viable drug targets and biomarkers for early diagnosis of the diseases. In this paper, we are reviewing various aspects associated with the disease and the recent trends that may have an application for the treatment of the neurodegenerative disorders.


Sign in / Sign up

Export Citation Format

Share Document